Case Comprehensive Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Case Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count).

407 total trials 55 currently recruiting 257 completed early-phase tilt top decile by trial count

Case Comprehensive Cancer Center: 407 sponsored US clinical trials, 55 recruiting.

Case Comprehensive Cancer Center sponsors 407 registered US clinical trials on ClinicalTrials.gov, 55 of them currently recruiting, and 257 completed. 13 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.

Top-decile sponsor footprint

Case Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 37/100

257 of 325 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

407 total, page 2 of 9

RECRUITING

Genomic Analysis of Families With a History of Discordant Cancers

NCT04860453

RECRUITING Early Phase 1

Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

NCT04332341

RECRUITING Phase 2

Single- vs. Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases

NCT04218617

RECRUITING

Proton Therapy Patient Registry

NCT02986048

RECRUITING Phase 1

Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

NCT01891318

ACTIVE NOT RECRUITING NA

Abbreviated MBCT for Depression in Older African American/Black Breast Cancer Survivors

NCT06336538

ACTIVE NOT RECRUITING NA

Developing Inclusive Support and Intervention for Spanish-speaking Latiné Prostate Cancer Survivors

NCT06435871

ACTIVE NOT RECRUITING NA

Individualized Treatments in Adults With Relapsed/Refractory Cancers

NCT06024603

ACTIVE NOT RECRUITING NA

Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program

NCT05831358

ACTIVE NOT RECRUITING Phase 1

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

NCT05209074

ACTIVE NOT RECRUITING NA

Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography

NCT04348123

ACTIVE NOT RECRUITING Phase 1

Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

NCT04620603

ACTIVE NOT RECRUITING Phase 2

CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

NCT04668885

ACTIVE NOT RECRUITING NA

Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue

NCT04545177

ACTIVE NOT RECRUITING Phase 2

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

NCT04010357

ACTIVE NOT RECRUITING Phase 1

Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma

NCT03713580

ACTIVE NOT RECRUITING Phase 1

Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

NCT03535350

ACTIVE NOT RECRUITING Phase 1

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

NCT03514069

ACTIVE NOT RECRUITING NA

Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions

NCT02802553

ACTIVE NOT RECRUITING Phase 1

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

NCT03277638

ACTIVE NOT RECRUITING

Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence

NCT03283540

ACTIVE NOT RECRUITING NA

Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors

NCT02956291

ACTIVE NOT RECRUITING Phase 1

Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases

NCT01843413

NOT YET RECRUITING NA

TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)

NCT07653594

NOT YET RECRUITING NA

Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS)

NCT07219745

NOT YET RECRUITING NA

Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)

NCT06811454

NOT YET RECRUITING Phase 2

Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)

NCT06084780

NOT YET RECRUITING NA

Improving Patient Understanding of Their Prostate Cancer Diagnosis Using AI

NCT07040501

NOT YET RECRUITING Phase 2

Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis

NCT07524634

NOT YET RECRUITING NA

A Study of Freeze-Dried Miracle Fruit (MiraBurst) on Participants Receiving Cancer Treatment

NCT07419581

NOT YET RECRUITING

Herbs & Supplements in Breast Cancer Usage, Impact, and Personalized Approaches for Diverse Populations

NCT06926530

NOT YET RECRUITING Phase 2

Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma

NCT07222657

COMPLETED

Collection of Peripheral Blood From Patients With Hematologic Malignancies With Thrombocytopenia

NCT06824727

COMPLETED Phase 2

Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses

NCT05923060

COMPLETED NA

Reiki Therapy to Improve Key Symptoms in Integrative Oncology Clinic (REIKI)

NCT06354049

COMPLETED NA

Effects of Lavender Aromatherapy on Patient Anxiety During Mohs Micrographic Surgery

NCT06167096

TERMINATED Phase 2

eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF

NCT05753735

COMPLETED Phase 2

Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses

NCT06027619

COMPLETED NA

NAVAH Impact on Radiation Therapy Completion in Black Breast & Prostate Cancer Patients

NCT05978232

TERMINATED NA

The Impact of Functional Medicine On Wound Healing From Delayed Autologous Breast Reconstruction

NCT05028101

COMPLETED NA

A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose

NCT05142358

TERMINATED Phase 2

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

NCT05289830

COMPLETED NA

Multidimensional Prehabilitation in Pancreatic Surgery for Pancreatic and Periampullary Neoplasms

NCT05225038

COMPLETED NA

Detection of Barrett s Esophagus in Patients Without GERD Symptoms

NCT04880044

COMPLETED NA

Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer

NCT04354675

COMPLETED NA

Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT

NCT04194840

COMPLETED NA

Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer

NCT04493034

COMPLETED NA

Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program

NCT04365569

TERMINATED NA

Free Flap Breast Reconstruction Using Virtual Surgical Planning and 3-D Modeling

NCT03949491

COMPLETED NA

Teach-back Method on Patient Satisfaction and Adherence to Wound Care Regimen

NCT04377971

← Previous Page 2 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 87
Phase 2 116
Phase 3 12
Phase 4 1

What is open in the Case Comprehensive Cancer Center pipeline

55 recruiting of 407 indexed (14% open); 257 completed (63%).

Phase mix: 13 late (III/IV) vs 203 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (18 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Case Comprehensive Cancer Center: open-pipeline peers nationwide

Peers matched on 407 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Case Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 10%15%20%25% Total trials Recruiting share Case Comprehensive Cancer CenterUniversity of NebraskaTakedaUniversity of Kansas Medical CenterSt. Jude Children's Research HospitalBeth Israel Deaconess Medical CenterWayne State UniversityUniversity of MichiganAlbany Medical College
Case Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Case Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 407 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

What to do with this Case Comprehensive Cancer Center page

407 registered trials is a research-attention snapshot, not an endorsement of Case Comprehensive Cancer Center or any single study.

  • 55 of Case Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Case Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Case Comprehensive Cancer Center pipeline card: 407 registered trials from official public datasets.Report a data error.